What is Endometrial Receptivity Genome Analysis (ERA)?

Endometrial Receptivity Genome Analysis is a state-of-the art diagnostic method, developed by our group (www.igeomix.com). This test allows evaluation of the endometrial receptivity status from a molecular point of view. This molecular tool enables assessment whether the endometrium is receptive for embryo implantation or not. This is performed by analyzing the expression of a group of genes related to endometrial receptivity.

The endometrial receptivity is the status in which the endometrium lining of the uterus is ready for embryo implantation. The time frame for embryo implantation is around day 17-21 in each menstrual cycle of a fertile woman, if fertilization happened previously.

What is ERA for?

The ERA test is used to assess endometrial status and to determine whether the patient’s endometrium had a receptive gene profile or not at the time in which the biopsy has been performed.

The human endometrium is a highly dynamic tissue that has the capacity to undergo physiological changes in response to steroid hormones, with the ultimate purpose to create a receptive status that is synchronized with the arrival of an implanting blastocyst (this is the name that is given to an embryo that is 5 days old after successful fertilization).

This test is done for those women, who have had multiple implantation failures with embryo transfers despite good morphological quality of the embryos. It is highly recommended in women who are younger than 35 years and have had 3 or more failures, or in women older than 35 years who have had 2 failures.

Further information will be discussed by our consultants in the outpatient department during the consultation. Please book an appointment with us.

Post Your Query